165 related articles for article (PubMed ID: 22180404)
1. Update of randomized trials in recurrent disease.
Pujade-Lauraine E; Alexandre J
Ann Oncol; 2011 Dec; 22 Suppl 8():viii61-viii64. PubMed ID: 22180404
[TBL] [Abstract][Full Text] [Related]
2. Treatment of recurrent ovarian cancer.
Pignata S; C Cecere S; Du Bois A; Harter P; Heitz F
Ann Oncol; 2017 Nov; 28(suppl_8):viii51-viii56. PubMed ID: 29232464
[TBL] [Abstract][Full Text] [Related]
3. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
[TBL] [Abstract][Full Text] [Related]
4. How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?
Ledermann JA; Wheeler S
Cancer Invest; 2004; 22 Suppl 2():2-10. PubMed ID: 15573740
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
Esposito F; Cecere SC; Magazzino F; Katsaros D; Ottaiano A; Gadducci A; Pisano C; Scalone S; Rabaiotti E; Salutari V; Cormio G; Canuto EM; Greggi S; Savarese A; Marinaccio M; Scollo P; Santeufemia DA; Sacco C; Facchini G; Pignata S
Oncology; 2014; 86(5-6):351-8. PubMed ID: 24942520
[TBL] [Abstract][Full Text] [Related]
6. Update on the role of topotecan in the treatment of recurrent ovarian cancer.
Herzog TJ
Oncologist; 2002; 7 Suppl 5():3-10. PubMed ID: 12324628
[TBL] [Abstract][Full Text] [Related]
7. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with topotecan in relapsed ovarian cancer.
Herzog TJ
Gynecol Oncol; 2003 Sep; 90(3 Pt 2):S3-7. PubMed ID: 13129489
[TBL] [Abstract][Full Text] [Related]
9. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
Markman M
Gynecol Oncol; 2001 Apr; 81(1):1-2. PubMed ID: 11277641
[No Abstract] [Full Text] [Related]
10. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Monk BJ; Coleman RL
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic agents should be integrated into the standard treatment for patients with ovarian cancer.
Burger RA
Ann Oncol; 2011 Dec; 22 Suppl 8():viii65-viii68. PubMed ID: 22180405
[TBL] [Abstract][Full Text] [Related]
12. The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
Zhang W; Shen Z; Luo H; Hu X; Zheng L; Zhu X
Curr Drug Targets; 2017; 18(10):1125-1131. PubMed ID: 27138763
[TBL] [Abstract][Full Text] [Related]
13. Update on randomized trials on recurrent disease.
González-Martín A
Ann Oncol; 2013 Dec; 24 Suppl 10():x48-x52. PubMed ID: 24265405
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapies for treatment of recurrent ovarian cancer.
Grisham RN; Hyman DM; Iyer G
Clin Adv Hematol Oncol; 2014 Mar; 12(3):158-62. PubMed ID: 24927263
[TBL] [Abstract][Full Text] [Related]
15. Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies.
Tomao F; Marchetti C; Romito A; Di Pinto A; Di Donato V; Capri O; Palaia I; Monti M; Muzii L; Benedetti Panici P
Expert Opin Pharmacother; 2017 Oct; 18(14):1443-1455. PubMed ID: 28521614
[TBL] [Abstract][Full Text] [Related]
16. Is combination chemotherapy superior to single-agent chemotherapy in second-line treatment?
González-Martín A;
Int J Gynecol Cancer; 2003; 13 Suppl 2():185-91. PubMed ID: 14656278
[TBL] [Abstract][Full Text] [Related]
17. [Recurrent and 2nd line therapy in ovarian carcinoma: an overview of conventional systemic therapy modalities].
du Bois A; Lück HJ; Meerpohl HG
Zentralbl Gynakol; 1997; 119(7):299-323. PubMed ID: 9340970
[TBL] [Abstract][Full Text] [Related]
18. Optimal assessment of response in ovarian cancer.
Eisenhauer EA
Ann Oncol; 2011 Dec; 22 Suppl 8():viii49-viii51. PubMed ID: 22180400
[TBL] [Abstract][Full Text] [Related]
19. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for ovarian cancer: current status and new treatments.
Ozols RF
Semin Oncol; 2006 Apr; 33(2 Suppl 6):S3-11. PubMed ID: 16716797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]